These results indicated that the combination of PARP and BLM inhibition by small molecule inhibitors (olaparib and ML216, respectively) exerted synthetic lethality effects, which provided a therapeutic strategy to kill olaparib-resistant tumor cells. Here, BLM is linked to neoplasm.